ATE243501T1 - Zubereitung mit gesteuerter freisetzung - Google Patents

Zubereitung mit gesteuerter freisetzung

Info

Publication number
ATE243501T1
ATE243501T1 AT95900570T AT95900570T ATE243501T1 AT E243501 T1 ATE243501 T1 AT E243501T1 AT 95900570 T AT95900570 T AT 95900570T AT 95900570 T AT95900570 T AT 95900570T AT E243501 T1 ATE243501 T1 AT E243501T1
Authority
AT
Austria
Prior art keywords
pct
active compound
polymer matrix
controlled release
release preparation
Prior art date
Application number
AT95900570T
Other languages
English (en)
Inventor
Yan Chen
Bruce Nathaniel Gray
Original Assignee
Sirtex Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3777364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE243501(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirtex Medical Ltd filed Critical Sirtex Medical Ltd
Application granted granted Critical
Publication of ATE243501T1 publication Critical patent/ATE243501T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95900570T 1993-11-18 1994-11-17 Zubereitung mit gesteuerter freisetzung ATE243501T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM249293 1993-11-18
PCT/AU1994/000708 WO1995013798A1 (en) 1993-11-18 1994-11-17 Controlled release preparation

Publications (1)

Publication Number Publication Date
ATE243501T1 true ATE243501T1 (de) 2003-07-15

Family

ID=3777364

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95900570T ATE243501T1 (de) 1993-11-18 1994-11-17 Zubereitung mit gesteuerter freisetzung

Country Status (9)

Country Link
US (1) US5932248A (de)
EP (1) EP0727984B1 (de)
JP (1) JP4619457B2 (de)
CN (1) CN1139380A (de)
AT (1) ATE243501T1 (de)
AU (1) AU693821B2 (de)
CA (1) CA2176933A1 (de)
DE (1) DE69432867T2 (de)
WO (1) WO1995013798A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775435B1 (fr) * 1998-02-27 2000-05-26 Bioalliance Pharma Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
WO1999049908A1 (en) 1998-03-31 1999-10-07 University Of Cincinnati Temperature controlled solute delivery system
CA2248592A1 (en) 1998-08-31 2000-02-29 Christopher D. Batich Microspheres for use in the treatment of cancer
IL144597A0 (en) * 1999-02-03 2002-05-23 Powderject Res Ltd Hydrogel particle formulations
NZ513981A (en) * 1999-03-08 2004-02-27 Powderject Res Ltd Delivery of microparticle formulations using needleless syringe device for sustained-release of bioactive compounds
EP1171118A2 (de) * 1999-04-09 2002-01-16 Jessie L.S. Au Verfahren und arzneimittel zur erhöhung der wirkstoffverabreichung an gewebe
JP2001031577A (ja) * 1999-07-16 2001-02-06 Fujibio Co Ltd キチン・キトサンによるシスプラチンの副作用防止方法及びそのための配合剤
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
CN101708165A (zh) * 2000-03-24 2010-05-19 生物领域医疗公司 用于主动栓塞术的微球体
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
AUPR098300A0 (en) * 2000-10-25 2000-11-16 Sirtex Medical Limited Polymer based radionuclide containing microspheres
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
DK1355566T3 (da) * 2000-12-18 2013-03-04 Univ Texas Lokal regional kemoterapi og radioterapi ved anvendelse af hydrogel in situ
DK1418890T3 (da) * 2001-08-16 2008-08-11 Baxter Int Drivmiddel-baserede mikropartikelformuleringer
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US8685427B2 (en) * 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
CN106344968B (zh) * 2003-02-12 2019-09-24 生物相容英国有限公司 组合物在制备用于在实体瘤的患者进行栓塞治疗中在循环系统中形成栓塞的药物中的用途
US20040161466A1 (en) 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
EP1592405B1 (de) * 2003-02-12 2008-05-28 Biocompatibles UK Limited Zusammensetzungen für die chemoembolotherapie solider tumoren
RU2426590C2 (ru) * 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
AU2004258971A1 (en) * 2003-07-22 2005-02-03 Baxter Healthcare S.A. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
WO2005087193A2 (en) * 2004-03-11 2005-09-22 Biocompatibles Uk Limited Chemoembolisation involving an anthracycline compound
WO2005107710A2 (en) * 2004-05-06 2005-11-17 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
US20060141046A1 (en) * 2004-05-06 2006-06-29 Ivrea Pharmaceuticals, Inc. Particles for the delivery of active agents
WO2005112894A1 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
CA2566199C (en) * 2004-05-12 2013-10-22 Baxter International Inc. Delivery of as-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
WO2006002365A2 (en) * 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
JP2008539259A (ja) * 2005-04-27 2008-11-13 バクスター・インターナショナル・インコーポレイテッド 表面を修飾した微粒子およびその形成方法および使用
EP2484344B1 (de) 2005-05-09 2016-02-10 Biosphere Medical, S.A. Zusammensetzungen und Verfahren zum Verwenden von Mikrokügelchen und nicht ionischen Kontrastmitteln
US8343546B2 (en) * 2005-09-13 2013-01-01 Coating Place, Inc. Ion exchange resin treated to control swelling
AU2007227312A1 (en) * 2006-03-21 2007-09-27 Alza Corporation Hydratable polymeric ester matrix for drug electrotransport
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP2056883B1 (de) 2006-08-04 2021-09-22 Baxter International Inc. Zusammensetzung auf mikrokügelchenbasis zur vorbeugung und/oder abwendung einer neuerkrankung an autoimmunem diabetes
CZ299053B6 (cs) * 2006-08-09 2008-04-09 Zentiva, A. S. Polymerní konjugáty doxorubicinu s pH-rízeným uvolnováním léciva a zpusob jejich prípravy
CZ2006592A3 (cs) * 2006-09-18 2008-03-19 Zentiva, A. S. Polymerní lécivo a zpusob jeho výroby
CA2663589A1 (en) * 2006-10-06 2008-05-22 Baxter International Inc. Microencapsules containing surface-modified microparticles and methods of forming and using the same
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
PT2126106T (pt) * 2007-02-23 2017-12-12 Sk Chemicals Co Ltd Proceso para produzir e purificar o fator viii e seus derivados
US8568777B2 (en) * 2007-03-30 2013-10-29 Monosol Rx, Llc Packaged film dosage unit containing a complexate
JP2008120838A (ja) * 2008-02-21 2008-05-29 Medgel Corp 配位結合を利用した薬物−高分子複合体製剤の調製方法
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8226601B2 (en) 2008-11-12 2012-07-24 Sanovas, Inc. Resector balloon system
US8540667B2 (en) * 2008-11-12 2013-09-24 Sanovas, Inc. Multi-balloon catheter for extravasated drug delivery
US20160074581A1 (en) 2014-09-17 2016-03-17 Lawrence J. Gerrans Modulated Drug Delivery
US8597239B2 (en) * 2011-03-01 2013-12-03 Sanovas, Inc. Abrading balloon catheter for extravasated drug delivery
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
TWI568453B (zh) * 2011-11-22 2017-02-01 原創生醫股份有限公司 具有螯合型複合微胞之藥物載體及其應用
ES2640363T3 (es) * 2012-11-15 2017-11-02 Utah-Inha Dds & Advanced Therapeutics Research Center Microgránulos biodegradables con capacidad de adsorción mejorada de fármacos anticancerígenos, que contienen albúmina y sulfato de dextrano, y método para su preparación
US9999676B2 (en) 2012-11-27 2018-06-19 Utah-Inha Dds & Advanced Therapeutics Research Center Biodegradable microbead comprising anionic polymer for improving adsorptive power to anticancer drugs, and method for preparing same
WO2014152790A1 (en) * 2013-03-14 2014-09-25 Drexel University Chelated drug delivery systems
WO2015111062A1 (en) * 2014-01-27 2015-07-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nanoencapsulation of hydrophilic active compounds
KR101614911B1 (ko) * 2014-05-14 2016-04-25 재단법인 유타 인하 디디에스 및 신의료기술개발 공동연구소 제 1 및 제 2 생분해성 마이크로 비드를 포함하는 화학색전용 조성물 및 이의 제조방법
CN105125522B (zh) * 2015-09-05 2018-08-21 四川大学 一种透明质酸-阳离子药物离子对微粒
US11246945B2 (en) * 2019-06-07 2022-02-15 National Defense Medical Center Cisplatin-loaded microbubbles, pharmaceutical composition for treatment of cancer, method for preparing pharmaceutical compositions and method for treating cancer
CN114947108A (zh) * 2022-04-28 2022-08-30 中国农业大学 酪蛋白胶束精准控释组合物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4946686A (en) * 1987-09-24 1990-08-07 Merck & Co., Inc. Solubility modulated drug delivery system
US5100668A (en) * 1988-06-14 1992-03-31 Massachusetts Institute Of Technology Controlled release systems containing heparin and growth factors
US5271945A (en) * 1988-07-05 1993-12-21 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
BR9107173A (pt) * 1990-12-21 1993-11-16 Richardson Vicks Inc Complexos de medicamentos de poliamina e resina
WO1992011844A1 (en) * 1991-01-03 1992-07-23 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
JPH07507768A (ja) * 1992-03-12 1995-08-31 アルカーメス　コントロールド　セラピューティクス，インコーポレイテッド Ａｃｔｈ含有マイクロスフェアの制御放出

Also Published As

Publication number Publication date
CN1139380A (zh) 1997-01-01
US5932248A (en) 1999-08-03
AU693821B2 (en) 1998-07-09
EP0727984B1 (de) 2003-06-25
CA2176933A1 (en) 1995-05-26
DE69432867T2 (de) 2004-04-22
JP4619457B2 (ja) 2011-01-26
AU8136394A (en) 1995-06-06
JPH09505059A (ja) 1997-05-20
DE69432867D1 (de) 2003-07-31
EP0727984A4 (de) 1997-09-10
WO1995013798A1 (en) 1995-05-26
EP0727984A1 (de) 1996-08-28

Similar Documents

Publication Publication Date Title
DE69432867D1 (de) Zubereitung mit gesteuerter freisetzung
MX9304975A (es) Una composicion en polvo para inhalacion y procedimiento para preparar la misma.
DK0697858T3 (da) Nasalt medikamentafgivelsessystem indeholdende nikotin
AU6421594A (en) High release solid preparation, preparation and use thereof
AU5680100A (en) Controlled release and taste masking oral pharmaceutical compositions
HU9603530D0 (en) Process for producing pharmaceutical compositions containing agent in polymer-matrix and in solid solution form and these medicaments
CA2225808A1 (en) Silver-based pharmaceutical compositions
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
CA2117351A1 (en) Preparation of Tablets of Increased Strength
AU2034395A (en) Composition consisting of a dendrimer and an active substance occluded in the dendrimer, a process for the preparation of such a composition and a process for releasing the active substance
ATE269709T1 (de) Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff
AU1884497A (en) New associations of active principles containing clopidogrel and an antithrombotic agent
CA2409292A1 (en) Tablets and methods for modified release of hydrophilic and other active agents
CA2263473A1 (en) Silver-based antimicrobial compositions
EP1003526A4 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendung
CA2039053A1 (en) Material for adsorbing pyrogen
ES2087652T3 (es) Composiciones cosmeticas y/o farmaceuticas y metodos para su uso en proteger tejidos del contacto con metales pesados.
ITMI932540A1 (it) Composizione farmaceutica
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound
GB9708092D0 (en) Materials and methods relating to inhibiting the interaction of p53 and mdm2
BR9307193A (pt) Processo para a preparação de uma formulação sólida de um agente de proteção de culturas e formulação sólida de agente de proteção de culturas
ATE363909T1 (de) Pharmazeutische zusammensetzungen mit wundheilender und anti-komplementärer wirkung die ein dextranderivat enthalten
WO1999021574A3 (en) Enhancement of morphogen activity
FI963567A (fi) Diklofenakki-Na:a sisältävä depottabletti
CA2273272A1 (en) Immediate release drug delivery forms

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties